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Abstract
Tyrosinemia type I (TYR I) is caused by autosomal recessive fumarylacetoacetate hydrolase 
deficiency and is characterized by development of severe liver disease in infancy and neurologic 
crises. If left untreated, most patients die of liver failure in the first years of life. Intervention with 
medication is effective when initiated during the first month of life. This improvement in the 
treatment of TYR I patients influenced the decision to include TYR I in the US Secretary of the 
Department of Health and Human Services’ (HHS) Recommended Uniform Screening Panel. 
However, while tyrosine is routinely measured in newborn screening (NBS) by tandem mass 
spectrometry (MS/MS), elevated tyrosine levels are not specific to TYR I. To improve the 
specificity of NBS for TYR I, several assays were developed to measure succinylacetone (SUAC) 
in dried blood spots (DBS). SUAC is a pathognomonic marker of TYR I, and its detection by NBS 
MS/MS is possible. This review of the current status of NBS for TYR I in the US is the result of 
discussions at the HHS Secretary’s (Discretionary) Advisory Committee on Heritable Disorders in 
Newborns and Children about the inconsistent implementation of effective NBS for TYR I in the 
US. We sought to understand the different TYR I screening practices in US NBS programs. 
Results indicate that 50 out of 51 NBS programs in the US screen for TYR I, and a successful 
SUAC performance evaluation scheme is available from the Centers for Disease Control and 
Prevention. Programmatic and methodological barriers were identified that prevent widespread 
adoption of SUAC measurements in NBS laboratories. However, since SUAC detection is 
currently the best approach to NBS for TYR I, a further delay of the addition of SUAC 
measurement into NBS procedures is discouraged. SUAC measurement should improve both the 
false positive and false negative rate in NBS for TYR I thereby yielding the desired benefits for 
affected patients at no expense to the overall population served.
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Tyrosinemia type I (TYR I, hepatorenal tyrosinemia; OMIM #276700) is caused by 
autosomal recessive fumarylacetoacetate hydrolase (FAH, EC 3.7.1.2) deficiency and is 
characterized by development of severe liver disease in infancy, renal impairment leading to 
hypophosphatemic rickets, and neurologic crises. Due to a founder effect among the French-
Canadian population, TYR I is common in Quebec (1:17,000 newborns) while it is less 
frequent elsewhere (ca. 1:100,000) [1]. At least 78 FAH gene mutations are known [2]. If 
left untreated most patients die of liver failure in the first years of life [1]. Dietary restriction 
of phenylalanine and tyrosine was the first attempt at treating this condition [3]. The goal 
was to prevent the accumulation of toxic metabolites by reducing the availability of tyrosine 
and its immediate precursor, the essential amino acid phenylalanine. While dietary treatment 
slows disease progression, long-term outcome with respect to complications, in particular 
the development of liver cancer, remained poor. As of the late 1970s into the 1990s liver 
transplantation became the treatment of choice as experience in pediatric organ 
transplantation increased and overall transplantation outcomes improved. Liver 
transplantation was considered curative of TYR I as long as treatment was initiated early 
and before significant kidney disease developed [4, 5]. Nevertheless, initial mortality of this 
invasive procedure remains relatively high (10–15%), long-term immunosuppression is 
required, and eventual organ failure often occurs [6].
In 1992, treatment with the herbicide 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-
cyclohexanedione (NTBC) was proposed because it is an effective inhibitor of 4-
hydroxyphenylpyruvic acid dioxygenase which is an enzyme in the tyrosine degradation 
pathway upstream of FAH [7]. This pharmacologic intervention prevents the formation of 
maleyl- and fumarylacetoacetate as well as relevant derivatives all of which are known to 
cause the pathologies observed in TYR I [8]. Along with a phenylalanine and tyrosine 
reduced diet, oral NTBC has become the mainstay of treatment for TYR I patients. NTBC is 
commercially available as Orfadin (Nitisinone) since 2002, and a report by Larochelle and 
colleagues describing the outcome of TYR I patients born between 1984 and 2004 in 
Quebec demonstrates that oral NTBC administration is not only better than dietary treatment 
alone and safer than organ transplantation, but particularly effective when initiated during 
the first month of life [9]. This dramatic improvement in the treatment of patients with a 
previously deleterious disease was the primary argument for TYR I inclusion in the US 
Secretary of Health and Human Services’ (HHS) Recommended Uniform Screening Panel 
(RUSP) [10].
However, while tyrosine, along with other amino acids, is routinely measured in newborn 
screening (NBS) dried blood spot (DBS) specimens by tandem mass spectrometry (MS/
MS), the finding of hypertyrosinemia is not a specific marker for TYR I and it is most often 
associated with common and benign transient tyrosinemia of the neonate (TTN). To further 
complicate matters, tyrosine concentrations in patients with TYR I overlap significantly with 
tyrosine concentrations in the unaffected population (Figure 1). To improve the specificity 
of NBS for TYR I, several assays were developed for the measurement of succinylacetone 
(SUAC) in DBS. SUAC is a pathognomonic marker of TYR I as it is only generated from 
maleyl- and fumarylacetoacetic acids when FAH is deficient. The initial approaches to its 
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measurement were indirect by determination of the activity of delta-aminolevulonic acid 
dehydratase which is inhibited by SUAC. Routine delta-aminolevulonic acid dehydratase 
activity measurements by a colorimetric method [11] were first implemented in Quebec’s 
NBS program. This assay was later modified by Holme et al [12]. Schulze and colleagues 
further improved the analysis through application of spectrophotometry which allowed for 
quantitative measurements and more objective result interpretation [13]. Allard and 
coworkers at the New England NBS program [14] developed an MS/MS based assay to 
measure SUAC directly. However, because SUAC extraction from DBS requires an acidic 
solution, simultaneous extraction of SUAC, amino acids and acylcarnitines with methanol is 
not possible. Allard therefore used the left-over DBS punch following the extraction of 
amino acids and acylcarnitines to extract and derivatize SUAC using hydrazine for 
subsequent analysis by MS/MS. The disadvantage of this approach is the need for additional 
equipment and personnel required to measure SUAC in each DBS; accordingly, this method 
was never implemented in a screening laboratory as a primary screening test. However, by 
mid-2008 the New England NBS program had modified this method to measure SUAC in 
multiple samples at a time and re-analyze only individual samples of a batch that revealed an 
elevated concentration of SUAC in the pooled samples [15]. Others opted to measure the 
isoxazole propionate derivative of SUAC in a two-tier approach where SUAC was measured 
only in samples with tyrosine concentrations above a lowered cut off [16]. But this approach 
was also deemed insufficiently sensitive given the significant overlap of tyrosine 
concentrations in TYR I patients and the normal population (Figure 1) [17]. Further work 
achieved the ability to measure SUAC, amino acids and acylcarnitines simultaneously. One 
method was designed to first extract and derivatize amino acids and acylcarnitines using 
butyl esterification (BE) and then extract and derivatize SUAC from the leftover DBS punch 
using hydrazine. The derivatized samples were then combined and amino acids, 
acylcarnitines and SUAC measured together by MS/MS. The concentration of SUAC was 
determined by comparison to isotopically labeled SUAC (13C5-SUAC) as internal standard 
[18, 19]. Another method achieved extraction of all analytes from the same sample by 
subsequent addition of methanol and hydrazine-containing solutions [20].
Because the methods described above are considered laboratory developed tests (LDT) they 
cannot be implemented by those NBS laboratories that are required by state law to use 
commercial, kit-based assays. These laboratories are limited to one of two options. 
PerkinElmer introduced the NeoBase™ Non-derivatized MSMS kit in 2008 [21]. This kit 
detects SUAC by extracting analytes from DBS with a solution comprising methanol and 
hydrazine, followed by derivatizing SUAC in the sample and measuring the derivatized 
SUAC along with non-derivatized (free acids, FA) amino acids and acylcarnitines by 
MS/MS. The SUAC derivative, 3-(5-methyl-1H-pyrazol-3-yl) propanoic acid (MPP), is 
quantified by use of a stable isotope-labeled analog of MPP as internal standard. The 
Austrian NBS program [22] evaluated another commercial MS/MS kit (Chromsystems 
MassChrom®) that allows for the combined sample preparation and measurement of AA, 
AC and SUAC without hydrazine. This kit applies a method similar to that of Turgeon et al 
[18] but was not available in the US as of May 2014.
A molecular genetic approach to NBS for TYR I has not yet been suggested and to date, it is 
unlikely to be cost effective because, even in populations where a specific mutation may be 
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prevalent, full gene sequencing and deletion testing would be required to ensure all patients 
are identified.
This review of the current status of NBS for TYR I in the US was prompted by discussions 
at the HHS Secretary’s (Discretionary) Advisory Committee on Heritable Disorders in 
Newborns and Children (S(D)ACHDNC), in particular the Laboratory Standards and 
Procedures Subcommittee, about the inconsistent implementation of effective NBS for TYR 
I in the USA despite the condition being included in the RUSP.
1.1. Objectives
We sought to understand the different TYR I screening practices in US NBS laboratories 
given the availability of analytical methods to detect SUAC in DBS specimens. While 50 of 
51 US NBS programs screen for TYR I [23], only 38 programs include testing of SUAC as a 
marker of TYR I. To better appreciate this limited implementation of SUAC measurement 
into routine NBS testing, we attempted to identify barriers faced by NBS programs that plan 
to, or would like to, adopt SUAC testing into their routine screening practice.
To gain an understanding of the performance of the various analytical approaches to NBS 
for TYR I that are available in the US, the outcome of the relevant metrics of the CDC’s 
NBS Quality Assurance Program (NSQAP) was reviewed. In addition, representative US 
NBS programs were asked to respond to a questionnaire aimed to explore the analytical and 
administrative experiences of programs that have and have not implemented SUAC testing 
to screen for TYR I. Programs not currently using SUAC measurement were also asked if 
their decision could be influenced by a recommendation from either the HHS Secretary or 
the S(D)ACHDNC to specifically employ SUAC testing in NBS for TYR I.
2. METHODS
2.1. Determination of TYR I NBS Performance Metrics
The NSQAP helps NBS laboratories ensure that testing accurately detects disorders, does 
not delay diagnosis, minimizes false-positive reports, and sustains high-quality laboratory 
performance [24]. For more than 30 years, NSQAP has performed this essential public 
health service, ensuring the quality and accuracy of screening tests for approximately 4 
million babies born each year in the USA. NSQAP provides two types of quality assurance 
materials and activities for testing in DBS, quality control (QC) and proficiency testing (PT) 
materials. These two activities are used to examine testing performance metrics by method 
and analyte, thus revealing potential analytic biases present in high-throughput 
methodologies used in NBS laboratories.
2.1.1. TYR I Proficiency Testing—NSQAP has provided a PT program for TYR I since 
2001. SUAC was added to the program in 2008 in response to an increasing number of state 
public laboratories adopting SUAC testing in their panels [25, 26]. The PT program 
distributes quarterly panels of blind-coded DBS specimens to participating laboratories and 
provides an independent external assessment of each laboratory’s performance. DBS 
materials for PT are certified for homogeneity, accuracy, stability, and suitability for kits 
manufactured by different commercial sources [24]. Data collected from PT participants 
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include cutoffs, methods used to assay tyrosine and/or SUAC (Supplemental Tables 1, 2), 
and presumptive specimen classification. When reporting cutoff values, NSQAP requests 
the decision level for reporting test results as presumptive positive (outside normal limits) or 
negative (within normal limits). The data collected is used to calculate false positive and 
false negative rates for specimens sent by NSQAP.
2.1.2. Tyrosine and SUAC Quality Control—Tyrosine was included in the CDC’s QC 
program in 2001 and in 2010 a SUAC QC program was launched by adding SUAC to the 
amino acid QC materials. DBS materials for QC are certified for homogeneity, accuracy, 
stability, and suitability for kits manufactured by different commercial sources [24]. 
Intended to supplement the participants’ method- or kit-control materials, the NSQAP QC 
materials allow participants to monitor the long-term stability of their assay reagents. The 
NSQAP provides two sets of 4-level QC DBS materials to participants every year. 
Laboratories report data for five independent runs, in duplicate (N=10 per laboratory). 
NSQAP estimates the method response to endogenous tyrosine and SUAC levels in its QC 
materials by performing weighted linear regression analyses for mean-reported 
concentrations versus enriched concentrations, and then extrapolates the regression lines to 
the Y-axis (intercept) to obtain an estimate of the observed endogenous analyte 
concentration for each method category.
2.1.3. Survey of Newborn Screening Programs—Between November and December 
2012, CDC conducted structured phone interviews with staff from NBS laboratories that 
have implemented SUAC testing and with staff from laboratories that have not implemented 
SUAC testing. The interviewees included broad representation from different US geographic 
regions and laboratories using different testing methods to detect SUAC. Interviewees were 
told their responses would be anonymous, consistent with CDC NSQAP’s data collection 
and dissemination practices. The questions posed to staff from 7 laboratories that have or 
have not implemented SUAC testing are listed in Table 1.
The CDC also conducted a web-based survey of state NBS programs to further identify 
hurdles related to SUAC test implementation (Supplemental Figure 1). The survey was 
approved by an Office of Management and Budget clearance process (OMB No. 0920-0879, 
expired 03/31/2014), which was designed for expedited approval of individual data 
collections from state public health officials and employees. In February 2013, NBS 
laboratory directors from 37 laboratories that serve 50 US states were e-mailed a link to an 
online survey hosted by www.surveymonkey.com. The survey contained 6 sections, but only 
sections 1, 4, 5, and 6 were relevant to NBS for TYR I. In section 1, the respondent typed 
the state(s) and/or region(s) served by their NBS laboratory in a textbox. Section 4 asked 
respondents to indicate whether or not they currently measure SUAC. An affirmative 
response to the question in section 4 led to 8 additional Yes/No questions and 1 open ended 
question about measuring SUAC (see Results for all questions). A negative response to the 
question in section 4 led to 10 additional Yes/No questions and 1 open ended question about 
barriers to measuring SUAC (see Results for all questions). The survey was closed in July 
2013. Survey results were downloaded from the website, captured in an Excel database, and 
are presented descriptively.
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3.1. Quality Assurance of SUAC Testing in DBS
3.1.1. Tyrosine and SUAC Proficiency Testing—Eight laboratories from the US, 23 
from outside the US, and two manufacturers of NBS reagent kits participated in the first 
SUAC PT challenge in 2008. A total of 85 laboratories (29 domestic, 53 international and 3 
manufacturers) participated in the latest SUAC PT challenge (January 2014) (Supplemental 
Table 3). In addition, a total of 272 laboratories (54 domestic, 208 international and 10 
manufacturers) participated in the latest Tyrosine PT challenge (January 2014) 
(Supplemental Table 4).
The comparisons of results by different methods are illustrated with the participants’ 
reported PT data for one selected challenge for each analyte during the year in NSQAP’s 
annual reports [27]. These are compared using bias plots (Figures 2, 3) that show the 
difference (positive or negative) by laboratory and method of the reported value subtracted 
from the expected value (i.e., CDC-measured endogenous level plus enrichment).
Good performance of a method or group of methods is indicated by a tight scatter within this 
interval. In general, the quantitative comparisons for PT challenges are reasonable within a 
method but they vary among methods. The PT quantitative results are grouped by kit or 
method to illustrate any method-related differences in analyte recoveries. The methods 
classified as “Non-kit” are considered LDTs and it is important to note that LDTs are 
grouped independent of analytical differences such as the choice of derivatizing reagent 
(hydrochloric acid in n-butanol, or acetyl chloride) used for amino acids and acylcarnitines, 
which can have an effect on a test’s performance. Accordingly, it is not unexpected that the 
bias plots reveal LDT performance to be more varied than the kit methods (NSQAP does not 
collect method information on LDTs). Overall, Figure 2 shows that most methods recover 
SUAC incompletely with some of the LDTs performing better than other LDTs and any kit-
based assay. Because SUAC recovery appears to be consistent among methods, this 
observation does not necessarily indicate poor clinical sensitivity of the test towards 
identifying cases of TYR I.
3.1.2. Tyrosine and SUAC Quality Control Results—Over 70 participating 
laboratories reported SUAC and tyrosine QC results from 2010–2013 (Supplemental Tables 
5–12). NSQAP estimated the method response to endogenous SUAC and tyrosine levels in 
its QC materials by performing weighted linear regression analyses for mean-reported 
concentrations versus enriched concentrations, and then extrapolated the regression lines to 
the Y-axis (intercept) to obtain an estimate of the observed endogenous analyte 
concentration for each method category. These estimates are reliable when enrichments are 
accurate, the analytical method gives a linear response across the range of the 
measurements, and the slopes for regression lines are approximately equal to one. 
Regression line slopes are an indirect measure of proportional bias by method. Lower slopes 
indicate lower analytical sensitivity/recovery. Data summary tables are published yearly by 
NSQAP in its annual report [27]. The tables show the analyte by series of QC lots, the 
number of measurements (N), the mean values, and the within-laboratory and total standard 
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deviations (SD) by kit or analytic method. NSQAP excluded values outside the 99% CI 
(outliers) from the calculations.
Statistical analysis of the reported QC data provides information about method-related 
differences in analytic recoveries and method biases. Because each QC lot series is prepared 
from one batch of hematocrit-adjusted, non-enriched blood, the endogenous concentration 
was the same for all specimens in a lot series. For regression analyses, NSQAP calculated 
the within-laboratory SD component of the total SD and used the reported QC data from 
multiple analytic runs. Moreover, NSQAP calculated the Y-intercept and slope in each table, 
using all analyte concentrations within a lot series (e.g., lots 221, 222, 223 and 224). A bias 
error in any one pool can markedly influence the slope and intercept. The Y-intercept 
provides one measure of the endogenous concentration level for an analyte. Participants also 
measured the endogenous concentrations by analyzing the non-enriched QC lots; the Y-
intercepts and measured endogenous levels for these analytes were similar for most 
methods. Ideally, the slope should be 1.0, and all slopes for SUAC fell within a range from 
0.2–0.8 (Supplemental Tables 5–8). In contrast, slopes for tyrosine in QC materials ranged 
from 0.7–0.9 (Supplemental Tables 9–12). The low SUAC slopes for some methods are due 
to recovery difficulties. Slope deviations might relate to analytic (dose-response) ranges for 
calibration curves or to poor recoveries for one or more specimens in the four-specimen QC 
set. Because the endogenous concentration was the same for all QC lots within a series, it 
should not affect the slope of the regression line among methods (Figure 4). Generally, slope 
values substantially different from 1.0 indicate that a method has an analytic bias.
3.2. Phone Interviews: Laboratories Currently Screening for TYR I through DBS SUAC 
assays
CDC presented the questions below to 7 staff members from state NBS laboratories that 
have implemented SUAC testing. CDC asked the questions italicized below, and 
summarized the responses from the experts after each question:
1. When did you implement population SUAC testing?
The earliest SUAC testing implementation reported date was 2007, and the latest 
was 2010.
2. What was the rationale for adopting SUAC testing?
All respondents reported that they needed a more specific marker for TYR I 
screening. Literature reports indicated that SUAC was a more specific marker for 
TYR I. In one case, a sample exchange program with another NBS laboratory 
confirmed cases that were being missed when only TYR cutoffs were used to 
evaluate samples. All TYR I cases were easily detected using the exchange 
laboratory’s SUAC assay.
3. How many samples are routinely screened every year?
All respondents stated their program’s latest test statistics. The experts were chosen 
to represent all US NBS programs, small and large, with birth rates ranging from 
60,000 to 500,000 births per year. Specific answers to this question are not 
included in this report to ensure respondent anonymity.
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4. Has your program identified pre-symptomatic TYR I patients through SUAC 
testing?
i. If yes, how many have you detected?
Six NBS programs reported identifying pre-symptomatic TYR I cases through 
SUAC testing. A total of 13 confirmed cases were reported. One laboratory did not 
provide the number of confirmed cases, only that they identified pre-symptomatic 
TYR I cases through SUAC testing.
5. How long did it take from the decision to implement SUAC testing to full 
population testing? In other words, take into account from when the decision was 
made to adopt SUAC testing up to the point of going “live” population screening 
(includes committee review and approval, laboratory pilot, etc).
Respondents reported an average SUAC testing implementation time of eight 
months.
6. What were the major challenges to implementing SUAC testing? How were they 
overcome?
Answers to this question varied in complexity. Most respondents cited the need for 
additional laboratory staff, additional instrumentation and laboratory space as their 
biggest challenge. Furthermore, the need for method re-validation was quoted as a 
concern by the majority of respondents. However, they all reported successful 
SUAC testing implementation in their programs.
One respondent reported that there was significant debate whether the cost/benefit justified 
the addition of a SUAC method. Although the S(D)ACHDNC’s Laboratory Standards & 
Procedures Subcommittee report (contained in the minutes from the January 15, 2008 
S(D)ACHDNC meeting; available at: http://www.hrsa.gov/advisorycommittees/
mchbadvisory/heritabledisorders/meetings/thirteenth/index.html) indicated that, 
“Subcommittee members agreed that a disorder that is already on the ACMG uniform panel 
should not be removed because of technological issues,” there was some disagreement 
among members of their program. Some thought that the issue should have been reviewed 
by S(D)ACHDNC like any other condition. The fact that it happened to already be on the 
US Recommended Uniform Screening Panel did not matter; therefore, at any cost, TYR I 
screening must remain on the list. As a result, their NBS program’s Medical Director issued 
a recommendation to implement SUAC testing.
3.3. Phone Interviews: Laboratories Currently Not Screening for TYR I through DBS SUAC 
assays
CDC presented the questions below to staff members from 7 state laboratories that have not 
implemented SUAC testing. We asked the questions italicized below, and summarize the 
responses from the experts after each question:
1. Is your laboratory planning to implement population-based SUAC testing?
If Yes, answer questions i–ii below. If No, skip to Question #2.
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i) Does your laboratory have, or is applying for, the necessary funding, 
infrastructure, staff and technical expertise to pilot SUAC testing? What are the 
missing elements needed by your laboratory to facilitate SUAC testing? 
(Examples: legislative mandate, safety considerations, etc.)
ii) What do you consider to be your laboratory’s largest challenge to 
implementing SUAC testing?
Answers to this question varied in complexity. Three respondents plan to 
implement SUAC testing, three do not, and one is not sure at this time.
Of the three respondents who plan to implement SUAC testing, one has completed 
a pilot study, and awaits their laboratory’s upcoming move to a new facility before 
initiating population SUAC testing. Another laboratory is currently evaluating the 
NeoBase™ Non-derivatized MSMS kit. The third laboratory has evaluated the 
NeoBase™ Non-derivatized MSMS kit, and does not plan to use it for SUAC 
testing. The biggest challenge noted by the respondents was securing the resources 
(i.e., funding, laboratory space) to add SUAC into their panel.
All three respondents who do not plan to implement SUAC testing cited their 
disapproval of the NeoBase™ Non-derivatized MSMS kit’s performance. 
Specifically, all respondents commented on the kit’s low bias/recovery of SUAC, 
as well as the need to constantly clean the MS/MS instrumentation. While they all 
agree that SUAC is an important analyte to measure, evaluating alternative 
methods on their MS/MS instruments is not possible due to contractual agreements 
with their vendors.
2. What is your laboratory’s level of interest in population-based SUAC testing?
Six experts responded that their program’s interest in population-based SUAC 
testing is high. One expert remarked that their program is only interested if a 
“better” kit becomes available.
3. Would a formal recommendation to measure SUAC as the primary marker for 
Tyrosinemia Type 1, issued by the US Department of Health and Human Services 
Secretary’s Advisory Committee on Heritable Disorders on Newborns and 
Children, increase the likelihood of SUAC testing by your laboratory?
Answers to this question varied in complexity. Some of the opinions offered by the 
respondents were very categorical in nature.
Two respondents answered that a formal recommendation from S(D)ACHDNC to measure 
SUAC as the primary marker for TYR I is not needed by their program.
Additionally, two respondents answered that a formal recommendation from S(D)ACHDNC 
to measure SUAC as the primary marker for TYR I would increase their likelihood of 
adopting SUAC testing, while one noted that such a recommendation would not be 
welcomed by their NBS program.
Three respondents stated that a formal recommendation would not increase the likelihood of 
adopting SUAC testing in their laboratory. Two of those experts noted that a formal 
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recommendation from S(D)ACHDNC may apply pressure on them to adopt an MS/MS kit 
they consider unsatisfactory. One expert opined that it is not the role of S(D)ACHDNC to 
recommend specific markers for disorders listed in the US RUSP, and does not believe it 
will be helpful to their NBS program.
3.4. Web Survey Results
Twenty-seven responses were received from state NBS laboratories before the survey’s 
closing date (27/37; response rate=73%). Fifteen of the 27 respondents (56%) measured 
SUAC, and 12 of the 27 (44%) did not measure SUAC at the time of the survey. Responses 
to additional Yes/No survey questions asked of laboratories that did or did not currently test 
for SUAC are presented in Tables 2 and 3, respectively.
The survey also asked laboratories currently testing for SUAC the following open- ended 
question: What were the major challenges to implementing SUAC testing in your laboratory, 
and how were they overcome? Selected responses to this question were:
• One of the major challenges was to find the time to validate the assay while 
processing daily patient samples for reporting
• The staff who brought SUAC on board in our state are no longer employed in our 
lab. A modified version of the home-brew Mayo Clinic method was the procedure 
used initially. Our lab began using NeoBase kits from Perkin Elmer a few years 
later, which includes SUAC screening
• Conversion of derivatized PerkinElmer NeoGram kit to non-derivatized NeoBase 
kit which allowed for the addition of SUAC
• In order to test all specimens for SUAC, rather than just those with elevated 
tyrosine, a complete revalidation of our test method would be required. We are 
currently validating the NeoBase method with SUAC testing so that all specimens 
can be evaluated.
• We did not have problems with the implementation, however establishing/
validating cut-offs and developing appropriate processes and work-flow required 
time and effort.
Additionally, the survey included the following open-ended question for laboratories not 
currently testing for SUAC: Please rank your laboratory’s greatest challenges to SUAC 
implementation (i.e. why would it be difficult to integrate SUAC testing into the current 
workflow of your NBS laboratory?) Selected responses to this question were:
• We currently use the NeoBase assay, and it appears to be very poor for accurately 
quantifying SUAC, especially at lower concentrations
• We use a derivatized kit of AA/AC screening. The non-derivatized kit has not 
worked well in our evaluation, therefore, we need to identify a method to allow us 
to maintain derivatization (via our kit) while adding SUAC
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• It would be difficult because we are using the derivatized Perkin Elmer kit. We do 
not wish to switch to the non-derivatized kit. Therefore, it would be difficult to get 
the additional lab equipment and space for testing
• We are waiting for PerkinElmer to make improvements in the NeoBase kit and to 
upgrade our MS/MS systems from Quattro Micro to TQDs. At that time, we will 
re-evaluate the NeoBase kit which provides SUAC detection
• The use of an extremely hazardous reagent in published methods. The increased 
cleaning needed MS/MS equipment and effect on other analytes is a worry
• Money, staff, equipment and space
4. CONCLUSIONS
TYR I is one of the original conditions recommended for NBS in the RUSP and 50 out of 51 
NBS programs in the US adopted this recommendation. However, at least 50% of TYR I 
patients have tyrosine concentrations in their NBS samples that overlap with the control 
range. Accordingly, programs that use only tyrosine as the screening marker will either miss 
a considerable proportion of TYR I cases or must accept a very high false positive rate. 
SUAC is a pathognomonic marker for TYR I, has been shown to be measurable efficiently 
in DBS by various NBS programs and applying different analytical approaches, and readily 
distinguishes patients from unaffected newborns (Figure 1). The SUAC performance 
evaluation schemes conducted by NSQAP confirm the concern of some NBS programs that 
omission of the BE derivatization step from the sample preparation reduces the recovery of 
SUAC from DBS. This is also supported, although not consistently, by data from the Region 
4 Genetics MS/MS Collaborative Project when comparing control ranges reported by NBS 
programs that either do or do not apply BE derivatization (Figure 5) [28].
Despite the analytical limitation Region 4 data also suggest that the lesser SUAC recovery 
does not diminish the sensitivity of NBS for TYR I (Figure 1). Test accuracy at even normal 
concentrations is an important criterion in clinical laboratory testing, particularly for 
quantitative analyses. However, the primary goal of NBS programs is to identify patients 
early so that treatment can be initiated and disabilities, morbidity, and mortality avoided. 
Moreover, our survey results suggest that a third of responders consider their testing only 
qualitative because quantitative data are not provided when reporting abnormal screening 
results (Table 2). This may further alleviate the need for absolute analytical accuracy. As 
long as a screening test reliably sorts samples into positive or negative screens, a degree of 
bias (inaccuracy) in quantitative results can be tolerated. Because 50 out of 51 NBS 
programs in the US already officially screen for TYR I, because NSQAP provides a SUAC 
performance evaluation scheme, and because SUAC determination is currently the best 
approach to NBS for TYR I, a further delay of the addition of SUAC measurement into NBS 
procedures is discouraged. SUAC measurement should improve both the false positive and 
false negative rate in NBS for TYR I thereby yielding the desired benefits for affected 
patients at no expense to the overall population served.
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Plots by Condition from the Region 4 MS/MS Collaborative Project [17]. Plots compare 
tyrosine (panel A) and SUAC (panel B) values observed in NBS samples of controls and 
TYR I patients based on sample preparation including derivatization (butyl esterification, 
BE) or not (free acid, FA). Black boxes indicate values observed in newborns with TYR I; 
grey boxes indicate values observed in control populations (upper whisker end: 99th 
percentile; top of box: 90th percentile; line in box: median; bottom of box: 10th percentile; 
lower whisker end: 1st percentile). Data are based on information provided by 15 NBS 
programs (including 9 US programs) using derivatization (BE) and 14 programs (including 
6 US programs) that do not derivatize (FA).
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Bias Plot of SUAC Values Reported by Domestic Laboratories – 2012. Note the scale-
changes of the Y-axis relative to the expected value for each plot. A reported value matching 
the expected value will show the illustrated value as falling on the “0” line of the plot. A 
reasonable bias is less than ± 20% of the expected value or within the 95% confidence 
interval (CI). “Deriv” refers to BE derivatization; “Non-deriv” refers to FA analysis.
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Bias Plot of Tyrosine Values Reported by Domestic Laboratories – 2013. Note the scale-
changes of the Y-axis relative to the expected value for each plot. A reported value matching 
the expected value will show the illustrated value as falling on the “0” line of the plot. A 
reasonable bias is less than ± 20% of the expected value or within the 95% confidence 
interval (CI). “Deriv” refers to BE derivatization. “Deriv” refers to BE derivatization; “Non-
deriv” refers to FA analysis.
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Mean Reported SUAC levels in NSQAP SUAC Quality Control Lots 221-224, 2012. 
“Derivatized” refers to BE derivatization; “Non-derivatized” refers to FA analysis.
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Control ranges for SUAC of different NBS programs using butyl ester derivatization (BE) or 
not (FA) during sample preparation for measurement of acylcarnitines, amino acids and 
SUAC. Data are from the Region 4 MS/MS Collaborative Project and sorted by each 
participant’s 10th percentile value for SUAC. (The target range shown is defined as the 
interval between the cumulative 99th percentile of SUAC in normal populations and the 
lowest 5th percentile of SUAC observed in TYR I cases [28].)
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Table 1
Questions to staff from 7 NBS laboratories that have or have not implemented SUAC testing.
Questions to NBS programs that measure SUAC Questions to NBS programs that do NOT measure SUAC
1 When did you implement population SUAC testing?
2 What was the rationale for adopting SUAC testing?
3 How many samples are routinely screened every year?
4 Has your program identified pre-symptomatic TYR I 
patients through SUAC testing?
5 How long did it take from the decision to implement 
SUAC testing to full population testing?
6 What were the major challenges to implementing SUAC 
testing? How were they overcome?
1 Is your laboratory planning to implement population-based 
SUAC testing?
2 What is your laboratory’s level of interest in population-
based SUAC testing?
3 Would a formal recommendation to measure SUAC as the 
primary marker for TYR I, issued by the US Department of 
Health and Human Services Secretary’s Advisory 
Committee on Heritable Disorders on Newborns and 
Children, increase the likelihood of SUAC testing by your 
laboratory?
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Table 2
Responses from Web-based Survey: Laboratories Currently Measuring SUAC (n=15).
Question Yes No N/A
a. Do you report tyrosine and SUAC levels for Tyrosinemia Type I? 10 5 0
b. Do you report SUAC levels alone for Tyrosinemia Type I? 7 8 0
c. Do you report tyrosine levels alone for Tyrosinemia Type I? 1 14 0
d. Do you perform SUAC analysis only in response to an elevated tyrosine? (i.e. SUAC analysis is only performed as a 
second-tier test) 1 14 0
e. Do you have cut offs for tyrosine based on birth weight? 1 13 1
f. Do you have cut offs for tyrosine based on gestational age? 0 14 1
g. Were budgetary restrictions an obstacle to SUAC implementation in your laboratory? 2 10 3
h. Were technical resources or personnel issues an obstacle to SUAC implementation in your laboratory? (e.g. were 
additional staff or instruments required for testing?) 3 11 1
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Table 3
Responses from Web-based Survey: Laboratories Currently Not Measuring SUAC (n=12).
Question Yes No N/A
a. Do you report tyrosine levels for Tyrosinemia Type I? 8 3 1
b. Do you have cut offs for tyrosine based on gestational age? 0 11 1
c. Do you have cut offs for tyrosine based on birth weight? 0 11 1
d. Is your laboratory considering the adoption of SUAC testing? 8 3 1
e. Does your laboratory have, or is it requesting, the necessary funding, infrastructure, staff, and technical expertise to pilot 
SUAC testing? 4 6 2
f. Are budgetary restrictions an obstacle to SUAC implementation in your laboratory? 5 6 1
g. Are insufficient technical resources or personnel an obstacle to SUAC implementation in your laboratory? (e.g. are 
additional staff or instruments required for testing?) 3 8 1
h. Is the availability of an appropriate assay an obstacle to SUAC implementation in your laboratory? 5 6 1
i. Would a formal recommendation to use SUAC as the primary marker for Tyrosinemia Type I, issued by the Secretary’s 
Advisory Committee on Heritable Disorders on Newborns and Children (SACHDNC), increase the likelihood of SUAC 
testing by your laboratory?
3 7 1
j. Would a formal recommendation to use SUAC as the primary marker for Tyrosinemia Type I, issued by the Secretary of 
the Department of Health and Human Services, increase the likelihood of SUAC testing by your laboratory? 3 7 1
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